glp-1 and substance use disorder medications are getting attention for their potential in addiction care. Here's what the research is finding. #AddictionTreatment #GLP1 #EmergingResearch GLP-1 receptor agonists show promise

In follow-up from the STEP 1 trial on semaglutide, average weight loss on semaglutide was 17.3% at week 68

Holistic Support: Access complementary services to enhance your results and address any concerns

That compares with six cases in patients prescribed non-GLP-1 diabetes drugs, calculated as a cumulative rate of 1.8%

A recent study published in JAMA Network Open has drawn attention to a possible, though rare, side effect: optic nerve disorders , specifically a condition known as non-arteritic anterior ischemic optic neuropathy (NAION)

doi: 10.1016/j.peptides.2005.02.016

Sections were mounted on slides and imaged using a Leica SP8 confocal microscope and Leica LAS X software